Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROSHARES TRUST (ZBIO) Other Non-Current Assets: 2023-2025

Historic Other Non-Current Assets for Zenas BioPharma (ZBIO) over the last 1 years, with Sep 2025 value amounting to $13.8 million.

  • Zenas BioPharma's Other Non-Current Assets rose 53.02% to $13.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.8 million, marking a year-over-year increase of 53.02%. This contributed to the annual value of $12.9 million for FY2024, which is 76.69% up from last year.
  • As of Q3 2025, Zenas BioPharma's Other Non-Current Assets stood at $13.8 million, which was up 17.00% from $11.8 million recorded in Q2 2025.
  • Over the past 5 years, Zenas BioPharma's Other Non-Current Assets peaked at $13.8 million during Q3 2025, and registered a low of $86,000 during Q3 2023.
  • Over the past 3 years, Zenas BioPharma's median Other Non-Current Assets value was $11.8 million (recorded in 2025), while the average stood at $9.7 million.
  • Data for Zenas BioPharma's Other Non-Current Assets shows a peak YoY spiked of 10,388.37% (in 2024) over the last 5 years.
  • Zenas BioPharma's Other Non-Current Assets (Quarterly) stood at $7.3 million in 2023, then soared by 76.69% to $12.9 million in 2024, then spiked by 53.02% to $13.8 million in 2025.
  • Its Other Non-Current Assets stands at $13.8 million for Q3 2025, versus $11.8 million for Q2 2025 and $12.8 million for Q1 2025.